Gumarontinib, a selective MET tyrosine kinase inhibitor (TKI) developed in China, is the third MET‐TKI approved in Japan for the treatment of NSCLC harboring MET exon 14 skipping alterations. This evidence concerns the gene MET and non-small cell lung carcinoma.